# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zelda Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET004-SYN-TD
- Date: 1930-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margot Ellery, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

One-week review, seen the same day by psychiatry with the coordinated specialty care team. **S**

## History of present illness

Ms. Fitzgerald returns one week after her first visit and is seen by Dr. Langford of the coordinated specialty care team on the same day. She takes risperidone 2 mg every night. She sleeps nine or ten hours and feels heavy and slow in the mornings. She has had no voices, no sense of being watched, and no racing thoughts. Her mood is still low but less tearful, and she has begun writing again for an hour a day. Her periods have still not returned; she has had no breast discharge. She is eating three small meals and has not danced. She is worried that medicines will make her gain weight and end her dancing. She has had no thoughts of suicide or self-harm. **S**

| Element | Detail |
|---|---|
| Risperidone | 2 mg at bedtime, every dose taken |
| Psychotic and manic symptoms | None |
| Mood | Low but improving; PHQ-9 9; item 9 scored 0 |
| Sleep | Nine or ten hours; slow in the mornings |
| Periods | Still absent; no breast discharge |
| Concern | Weight gain and her dancing |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the mornings; weight stable |
| Genitourinary | Positive | No periods for about five months; no pelvic pain |
| Endocrine | Negative | No breast discharge; no heat or cold intolerance |
| Neurological | Negative | No restlessness, stiffness, or tremor |
| Psychiatric | Positive | Low mood, improving; no voices, racing thoughts, or thoughts of suicide or self-harm |

5 systems reviewed. **S**

## Current medications

- Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital) **S**
- Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 51 kg; BMI 18.7 kg/m². All vital signs are synthetic.

PHQ-9: 9. All results are synthetic.

## Change since baseline

- PHQ-9: 11 at baseline, 9 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Slim and well; weight 51.0 kg, BMI 18.7; waist 66 cm; blood pressure 106/66, pulse 76 |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements; AIMS score 0 |
| Psychiatric | Quiet, reactive affect; organized; no psychotic or manic features; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **First episode of psychosis with marked mood symptoms, provisional diagnosis** (F29). No psychotic or manic symptoms on risperidone, with a depressive phase easing. Dr. Langford agrees that the history points most strongly to bipolar I disorder with psychotic features but that the order of the mood and psychotic symptoms is not yet clear, so the diagnosis stays provisional. To prevent another episode she advises lithium, the first choice for long-term prevention. Baseline creatinine 0.72 mg/dL, eGFR 116, TSH 2.1 mIU/L and calcium 9.4 mg/dL are normal, and a urine pregnancy test today is negative. Valproate is avoided because of its risks in pregnancy. Safety reviewed: no thoughts of suicide or self-harm; the safety plan and the 988 Suicide & Crisis Lifeline are in her phone; lithium will be dispensed in small amounts while her mood is low. **S**
   - Start lithium carbonate 300 mg twice daily.
   - Lithium level 5 to 7 days after starting, 12 hours after the evening dose.
   - Continue risperidone 2 mg for now and change one medicine at a time.
   - Enroll in the coordinated specialty care program.
   - Use condoms reliably; discuss a long-acting method at the next visits.
2. **Secondary amenorrhea** (N91.1). Periods stopped about four months before the admission, during very heavy training at a low weight, which points to low energy availability; prolactin 62 ng/mL on risperidone may now be adding to it. Pregnancy test negative. **S**
   - Repeat prolactin at the next check; if it stays high and her periods do not return, switch from risperidone to an antipsychotic that spares prolactin.
   - Sports dietitian appointment arranged; no dancing until she has seen the dietitian.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Risperidone 2 mg; full adherence; no psychotic or manic symptoms |
| Survey | Manic, depressive, and psychotic symptoms, and early warning signs | Every visit | Completed today | No manic or psychotic symptoms; depressive phase easing |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | Morning sedation; no akathisia or parkinsonism |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | Baseline AIMS score 0, done with the consultation |
| Examination | Weight and BMI | Every visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 51.0 kg (BMI 18.7); waist 66 cm |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 106/66 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Glucose 84 mg/dL and A1c 5.0% at intake; next at 12 weeks to 4 months |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at intake; next at 12 weeks to 4 months |
| Laboratory | Prolactin | When there are symptoms of high prolactin, such as missed periods | Up to date | 62 ng/mL at intake with absent periods; repeat at the next check |
| Laboratory | Electrocardiogram | Before lithium if over 40 or with heart disease; before an antipsychotic with cardiac risk factors | Not indicated | Age 29, no heart disease, fainting, or family history of sudden death |
| Laboratory | Creatinine and eGFR on lithium | Baseline, every 2 to 3 months for 6 months, then every 6 to 12 months | Up to date | Baseline creatinine 0.72 mg/dL, eGFR 116, a week ago |
| Laboratory | TSH on lithium | Baseline, once or twice in the first 6 months, then every 6 to 12 months | Up to date | Baseline TSH 2.1 mIU/L a week ago |
| Laboratory | Calcium on lithium | Baseline, then yearly | Up to date | Baseline calcium 9.4 mg/dL a week ago |
| Laboratory | Lithium level (12-hour trough) | 5 to 7 days after starting and after any change until stable, then every 3 to 6 months | Due | Lithium started today; level ordered for 5 to 7 days from now |
| Medication safety | Lithium side effects and sick-day rules | At the start and every visit | Completed today | Tremor, thirst, nausea and signs of toxicity explained; take with food; keep drinking normally; no anti-inflammatory painkillers |
| Medication safety | Pregnancy prevention on lithium; valproate avoided | Before starting and at each visit until a reliable method is in place | Completed today | Urine pregnancy test negative today; valproate avoided; the small risk of heart defects with lithium early in pregnancy explained; condoms reliably for now |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 9, from 11; item 9 scored 0 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan reviewed; no firearm access; lithium dispensed two weeks at a time |
| Self-management | Sleep | Every visit | Completed today | Nine or ten hours on risperidone; regular times agreed |
| Self-management | Eating, exercise, and periods | Every visit while periods are absent or weight is low | Completed today | SCOFF 1 of 5 a week ago; three small meals; not dancing; periods absent; dietitian arranged |
| Referral | Psychiatry consultation | At the start of treatment for a first episode | Completed today | Seen by Dr. Langford today |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Enrolled today |

## Goal progress

- No manic, depressive or psychotic episode and no readmission through six months. In progress; target 1930-10-26. **S**
- Lithium trough level 0.6 to 0.8 mmol/L with normal kidney and thyroid tests at six months. In progress; target 1930-10-26. **S**
- Periods return and prolactin is normal by three months. In progress; target 1930-08-10. **S**
- BMI at least 19, with food matched to her training, by six months. In progress; target 1930-10-26. **S**
- PHQ-9 score below 5 by six months. In progress; target 1930-10-26. **S**

## Medication changes

- Started: Lithium carbonate 300 mg oral capsule, one capsule by mouth twice daily **S**

## Guideline basis

- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023), Focus (American Psychiatric Publishing)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Lithium level in 5 to 7 days at the laboratory. Visit in three weeks with lithium level, creatinine, electrolytes, prolactin, and the PHQ-9. Care coordinator weekly; dietitian next week. **S**
- Next scheduled visit 1930-06-08: lithium level after the sick visit, prolactin, and the antipsychotic plan. **S**
